MHRA reports on thrombolytic events following Covid vaccination

  • Home
  • News
  • MHRA reports on thrombolytic events following Covid vaccination
NCL Wide
Add to CPD

The Medicines and Healthcare Products Regulatory Authority (MHRA) published its weekly summary of Yellow Card reporting for Covid-19 vaccines on 21 March 2021, which includes an update on thrombosis.  

In a reactive media statement from MHRA, Dr June Raine, MHRA Chief Executive, said:

“The benefits of Covid-19 Vaccine AstraZeneca in preventing Covid-19 infection and its complications continue to outweigh any risks and the public should continue to get their vaccine when invited to do so.

“As published in our most recent weekly summary of Yellow Card reporting for Covid-19 vaccines, up to and including 24 March we had received 22 reports of CVST and 8 reports of other thrombosis events with low platelets, out of a total of 18.1 million doses of Covid-19 Vaccine AstraZeneca given by that date. There were no reports for the Pfizer/BioNTech vaccine. Our thorough review into these reports is ongoing.

“We are asking healthcare professionals to report any cases they suspect to be linked with Covid-19 vaccination via the Coronavirus Yellow Card website.”

The British Society for Haematology has issued guidance on thrombosis and thrombocytopenia possibly occurring after vaccination with Covid-19 vaccines. This includes information on presentation and typical laboratory features, and treatment recommendations. The guidance also includes advice on recommended investigations for possible cases.

Expiry date: Jun 5th, 2021